WO2004057030A3 - Methods and compositions relating to drug-induced arrhythmia - Google Patents

Methods and compositions relating to drug-induced arrhythmia Download PDF

Info

Publication number
WO2004057030A3
WO2004057030A3 PCT/IB2003/005951 IB0305951W WO2004057030A3 WO 2004057030 A3 WO2004057030 A3 WO 2004057030A3 IB 0305951 W IB0305951 W IB 0305951W WO 2004057030 A3 WO2004057030 A3 WO 2004057030A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
methods
induced arrhythmia
compositions relating
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2003/005951
Other languages
French (fr)
Other versions
WO2004057030A2 (en
Inventor
Amy Regina Mank-Seymour
Patrice Marie Milos
Aidan Colman Power
Jodi Lyn Richmond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Priority to JP2004561841A priority Critical patent/JP2006511218A/en
Priority to EP03777083A priority patent/EP1579003A2/en
Priority to AU2003286340A priority patent/AU2003286340A1/en
Publication of WO2004057030A2 publication Critical patent/WO2004057030A2/en
Publication of WO2004057030A3 publication Critical patent/WO2004057030A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention features plymorphisms in genes encoding cardiac potassium channels that are predictive of a subject’s susceptibility to developing a drug-induced arrhythmia. The present invention also provides methods of genotyping subjects to determine whether they carry the polymorphisms.
PCT/IB2003/005951 2002-12-21 2003-12-10 Methods and compositions relating to drug-induced arrhythmia Ceased WO2004057030A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2004561841A JP2006511218A (en) 2002-12-21 2003-12-10 Methods and compositions related to drug-induced arrhythmias
EP03777083A EP1579003A2 (en) 2002-12-21 2003-12-10 Methods and compositions relating to drug-induced arrhythmia
AU2003286340A AU2003286340A1 (en) 2002-12-21 2003-12-10 Methods and compositions relating to drug-induced arrhythmia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43547002P 2002-12-21 2002-12-21
US60/435,470 2002-12-21

Publications (2)

Publication Number Publication Date
WO2004057030A2 WO2004057030A2 (en) 2004-07-08
WO2004057030A3 true WO2004057030A3 (en) 2004-10-28

Family

ID=32682247

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/005951 Ceased WO2004057030A2 (en) 2002-12-21 2003-12-10 Methods and compositions relating to drug-induced arrhythmia

Country Status (5)

Country Link
US (1) US20050059032A1 (en)
EP (1) EP1579003A2 (en)
JP (1) JP2006511218A (en)
AU (1) AU2003286340A1 (en)
WO (1) WO2004057030A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20051047A1 (en) * 2005-06-07 2006-12-08 Irccs Fond Salvatore Maugeri C MUTATIONS ASSOCIATED WITH THE LONG QT SYNDROME AND THEIR DIAGNOSTIC USE
US20090325156A1 (en) * 2005-11-10 2009-12-31 Government of the United States of America, as Represented by Secretary, Dept. of Human Services Materials and methods for abcb1 polymorphic variant screening, diagnosis, and treatment
JP5604616B2 (en) * 2007-12-18 2014-10-08 公益財団法人ヒューマンサイエンス振興財団 Test method and test kit for type 2 diabetes using gene polymorphism
CA2757723C (en) 2009-04-06 2018-07-24 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
JP5881597B2 (en) 2009-04-06 2016-03-09 ヴァンダ ファーマシューティカルズ インコーポレイテッド How to predict a predisposition to QT prolongation
EP2416779B1 (en) 2009-04-06 2016-03-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
EP3354753B1 (en) * 2009-04-06 2020-02-12 Vanda Pharmaceuticals Inc. Method of treatment based on polymorphisms of the kcnq1 gene
JP6459458B2 (en) * 2014-03-03 2019-01-30 ソニー株式会社 Cell evaluation device

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033401A2 (en) * 1999-02-26 2000-09-06 Genset Expressed sequence tags and encoded human proteins
WO2002008381A2 (en) * 2000-07-20 2002-01-31 University Of Utah Research Foundation Common polymorphism in scn5a implicated in drug-induced cardiac arrhythmia
US6451534B1 (en) * 1995-12-22 2002-09-17 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
US6458542B1 (en) * 1999-10-08 2002-10-01 Vanderbilt University Method of screening for susceptibility to drug-induced cardiac arrhythmia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451534B1 (en) * 1995-12-22 2002-09-17 University Of Utah Research Foundation KVLQT1—a long QT syndrome gene
EP1033401A2 (en) * 1999-02-26 2000-09-06 Genset Expressed sequence tags and encoded human proteins
JP2001269182A (en) * 1999-02-26 2001-10-02 Genset Sequence tags and encoded human proteins
US6458542B1 (en) * 1999-10-08 2002-10-01 Vanderbilt University Method of screening for susceptibility to drug-induced cardiac arrhythmia
WO2002008381A2 (en) * 2000-07-20 2002-01-31 University Of Utah Research Foundation Common polymorphism in scn5a implicated in drug-induced cardiac arrhythmia

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ABBOTT G W ET AL: "MRP1 FORMS IKR POTASSIUM CHANNELS WITH HERG AND IS ASSOCIATED WITH CARDIAC ARRHYTHMIA", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 97, December 1999 (1999-12-01), pages 175 - 187, XP002944234, ISSN: 0092-8674 *
DATABASE EMBL 23 October 2003 (2003-10-23), WALBOT V.: "Maize genomic sequences found using engineered RescueMu transposon", XP002290792, Database accession no. CG710829 *
DATABASE EMBL 4 September 2002 (2002-09-04), DUMAS MILNE ET AL.: "Sequence tag and encoded human protein", XP002290798, Database accession no. BD041401 *
DATABASE GENESEQ 6 October 2000 (2000-10-06), DUMAS MILNE ET AL.: "Human secreted protein 5' EST", XP002290793, Database accession no. AAC17656 *
SPLAWSKI I ET AL: "Genomic Structure of Three Long QT Syndrome Genes:KVLQT1, HERG,andKCNE1", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 51, no. 1, 1 July 1998 (1998-07-01), pages 86 - 97, XP004449405, ISSN: 0888-7543 *
WANG Q ET AL: "POSITIONAL CLONING OF A NOVEL POTASSIUM CHANNEL GENE:KVLQT1 MUTATIONS CAUSE CARDIAC ARRHYTHMIAS", NATURE GENETICS, NEW YORK, NY, US, vol. 12, no. 1, 12 January 1996 (1996-01-12), pages 17 - 23, XP002916129, ISSN: 1061-4036 *

Also Published As

Publication number Publication date
JP2006511218A (en) 2006-04-06
WO2004057030A2 (en) 2004-07-08
AU2003286340A1 (en) 2004-07-14
US20050059032A1 (en) 2005-03-17
EP1579003A2 (en) 2005-09-28

Similar Documents

Publication Publication Date Title
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
WO2004063362A3 (en) Cell cycle progression proteins
WO2005059108A3 (en) Gene expression profiles and methods of use
AU2003214604A8 (en) Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same
AU2003269938A8 (en) Nucleotide sequences specific to francisella tularensis and methods for the detection of francisella tularensis
AU2003259285A8 (en) Methods of identifying adipocyte specific genes, the genes identified, and their uses
WO2005082341A3 (en) NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
WO2005032495A3 (en) Gene expression profiles and methods of use
WO2003010336A3 (en) Molecular markers for hepatocellular carcinoma
AU2003291358A1 (en) Methods for predicting whether subjects with mild cognitive impairment (mci) will develop alzheimer's disease
WO2006069339A8 (en) Genetic variants of vkorci predicting warfarin sensitivity
WO2004026107A3 (en) Kits and methods for assessing skin health
AU2003217652A8 (en) Methods for continuous performance testing
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
WO2005013809A3 (en) Diagnostic and therapeutics for osteoporosis
WO2005001042A8 (en) Smooth muscle progenitor cells
WO2004005886A3 (en) Kits and methods for assessing cardiovascular health
WO2004016768A3 (en) Compositions and methods for inferring ancestry
WO2003031651A3 (en) Method of determining susceptibility to inflammatory bowel disease
WO2002080755A3 (en) Kits and methods for assessing oxidative stress
AU2003286340A1 (en) Methods and compositions relating to drug-induced arrhythmia
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers
AU2003218601A1 (en) Phox2b polymorphisms as hirschsprung's disease diagnostic markers and methods based thereon
WO2006063703A8 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: EXCEPT/SAUF EG, NI, PG, SY, AP (BW))

WWE Wipo information: entry into national phase

Ref document number: 2004561841

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003777083

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003777083

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003777083

Country of ref document: EP